Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Recruiting · NCT04878029 · Registry updated 2026-04-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma | Recruiting | Phase 1 | 2026-04-29 | NCT04878029 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Emory University | 393 |
| Exelixis | 77 |
| National Cancer Institute (NCI) | 3015 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University Hospital/Winship Cancer Institute | Atlanta | United States | 299 |